Advance-HTA Capacity Building Workshop

Warsaw, 25-26 September 2014


The application of HTA has expanded into Eastern Europe and its uptake has increased over the past few years. Some countries have extended the use of HTA to support rational and transparent spending decisions, while others, such as Poland, use it as an explicit criterion for setting the price and/or reimbursement of medicines. Slovenia is actually in the process of developing an HTA system.

There is no doubt that many advances have been made in the recent years in Europe regarding the implementation of HTA. Yet, in many Member States, particularly in South & Eastern Europe, HTA is still in a nascent phase and much can be done to inform local decision-makers about uses of HTA in different setups.

The workshop is therefore an opportunity to build HTA capacity, outline the options available for decision-makers and debate the actions required for this purpose, tailor-made for the needs of the countries in this region.


  • Introduce the principles, models and structure of HTA, including specific considerations for pharmaceuticals, medical devices and orphan medicinal products.
  • Showcase best practices and lessons learned from countries that already use HTA.
  • Provide recommendations for the strengthening and the implementation of HTA as a tool for decision-making and efficient resource allocation at national level (as well as supra-national and international levels).
  • Discuss future developments in HTA and their policy implications
  • Foster international collaboration and create a network for exchange of expertise

The workshop took place in Warsaw, Poland, on 25-26 September 2014. It was attended by 29 participants, mainly policy makers working in public institutions such as Ministries of Health, Health Insurance Funds, National Health Services and HTA Agencies. In total, 13 countries were represented: Bulgaria, Croatia, Cyprus, Estonia, Greece, Hungary, Latvia, Poland, Serbia, Slovekia, Russia, Turkey and Ukraine.

Agenda and Resources

The 2-day workshop included 6 sessions:

  • Introduction to HTA
  • HTA Experiences in South and East Europe
  • Critical Issues in Appraisal of Medical Technologies
  • HTA in Context: Medical Devices and Orphan Drugs
  • Empirical Evidence on Use of HTA
  • The Way Forward

Click here to access the full program.

All presentations delivered during the workshop are provided below:

HTA: Models, Costs and Benefits

Processes and Evidence Requirements

HTA and the Patient

Survey Results in South and East Europe

HTA in Poland: the process of adoption and current application

The experiences of GYEMSZI TEI - the Hungarian HTA office

HTA in Croatia: First Five Years

Lessons Learned and Way Forward

Value for money

Value assessment methods and application of Multiple Criteria Decision Analysis for HTA

Methods of preference elicitation (EQ5D and measures of utility)

Willingness to pay thresholds and their use

Medical Devices: Differences vs. other technologies especially pharmaceuticals

Medical Devices: Taxonomy

Networks for rare diseases

The NICE experience

EUnetHTA Core model

Risk sharing agreements

Risk sharing agreements: the case of Sweden


Based on feedback received from participants, the workshop was a success in terms of quality of speakers, program’s structure and content, and general workshop’s administration. In fact, more than 85% of participants stated they would recommend the workshop to colleagues.

“On behalf of my colleagues from the National Health Service, we would like to thank you and your team for this well organised meeting. We received new knowledge and learned from other countries’ experiences”

Future Activities

A second HTA Capacity Building Workshop for South and South Eastern Europe took place in September 2015. It was an opportunity to showcase the results of Advance-HTA research activities.

Full title Advancing and strengthening the methodological tools and policies relating to the application and implementation of Health Technology Assessment (HTA)
Project number 305983
CoordinationLSE Health
Consortium 13 partners

The research leading to these results has received funding from the European Community's Seventh Framework Programme FP7/2007-2013 under grant agreement No. 305983.